CanSino Biologics Inc.
CASBFOTCHealthcare● Active
$3.97
+$0.97(+32.33%)
Market Cap$1.4B
P/E Ratio—
52W High$6.99
52W Low$3
CanSino Biologics Inc. (CASBF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CASBF · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 28, 2026EPS Actual
-$0.02
Revenue
$0.03B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 28, 2026
After Market Close
CASBF reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.20
Rev. $3.50B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.20
Rev. Est.$3.50B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 21, 2026 | — | — | — | — | — | — |
| — Q2 FY2026 | Apr 28, 2026 | — | -$0.02 | — | $0.03B | — | — |
| ▼ Q1 FY2026 | Mar 30, 2026 | $0.04 | $0.01 | -82.4% | $0.05B | $0.05B | +14.3% |
| ▲ Q4 FY2025 | Oct 27, 2025 | -$0.00 | $0.02 | +2476.9% | $0.04B | $0.05B | -3.4% |
| ▲ Q3 FY2025 | Aug 20, 2025 | -$0.01 | -$0.00 | +92.1% | $0.03B | $0.05B | -27.8% |
| ▼ Q2 FY2025 | Apr 29, 2025 | -$0.00 | -$0.01 | -3335.0% | $0.02B | — | — |
| ▼ Q4 FY2024 | Dec 31, 2024 | -$0.02 | -$0.09 | -324.9% | $0.04B | $0.04B | -11.6% |
| ▲ Q4 FY2024 | Oct 29, 2024 | -$0.05 | $0.00 | +103.5% | $0.04B | $0.03B | +22.0% |
Q3 FY2026
Aug 21, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 28, 2026
EPS Actual
-$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
$0.03B
Q1 FY2026
Mar 30, 2026Miss
EPS Actual
$0.01
EPS Est.
$0.04
EPS Surpr.
-82.4%
Revenue
$0.05B
Q4 FY2025
Oct 27, 2025Beat
EPS Actual
$0.02
EPS Est.
-$0.00
EPS Surpr.
+2476.9%
Revenue
$0.04B
Q3 FY2025
Aug 20, 2025Beat
EPS Actual
-$0.00
EPS Est.
-$0.01
EPS Surpr.
+92.1%
Revenue
$0.03B
Q2 FY2025
Apr 29, 2025Miss
EPS Actual
-$0.01
EPS Est.
-$0.00
EPS Surpr.
-3335.0%
Revenue
$0.02B
Q4 FY2024
Dec 31, 2024Miss
EPS Actual
-$0.09
EPS Est.
-$0.02
EPS Surpr.
-324.9%
Revenue
$0.04B
Q4 FY2024
Oct 29, 2024Beat
EPS Actual
$0.00
EPS Est.
-$0.05
EPS Surpr.
+103.5%
Revenue
$0.04B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.31 | $0.31 | $0.31 | 1 |
| Q3 FY2025 | $-0.00 | $-0.00 | $-0.00 | 1 |
| Q2 FY2025 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Q4 FY2024 | $-0.61 | $-0.61 | $-0.61 | 1 |
| Q3 FY2024 | $-0.35 | $-0.35 | $-0.35 | 1 |
| Q2 FY2024 | $-0.37 | $-0.37 | $-0.37 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.3B | $0.3B | $0.3B | 1 |
| Q3 FY2025 | $0.3B | $0.3B | $0.3B | 1 |
| Q2 FY2025 | $0.3B | $0.3B | $0.3B | 1 |
| Q4 FY2024 | $0.3B | $0.3B | $0.3B | 1 |
| Q3 FY2024 | $0.2B | $0.2B | $0.2B | 1 |
| Q2 FY2024 | $0.2B | $0.2B | $0.2B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | Apr 28, 2026 | — | $3.86 | $3.86 | +0.00% |
| ▼ Q1 FY2026 | Mar 30, 2026 | -82.4% | $3.86 | $3.86 | +0.00% |
| ▲ Q4 FY2025 | Oct 27, 2025 | +2476.9% | $5.30 | $5.60 | +5.66% |
| ▲ Q3 FY2025 | Aug 20, 2025 | +92.1% | $6.26 | $6.26 | +0.00% |
| ▼ Q2 FY2025 | Apr 29, 2025 | -3335.0% | $3.20 | $3.20 | +0.00% |
| ▼ Q4 FY2024 | Dec 31, 2024 | -324.9% | $4.00 | $4.00 | +0.00% |
| ▲ Q4 FY2024 | Oct 29, 2024 | +103.5% | $3.51 | $3.51 | +0.00% |
| ▲ Q3 FY2024 | Aug 29, 2024 | +39.8% | $1.98 | $1.98 | +0.00% |
Q2 FY2026+0.00%
Report Date
Apr 28, 2026
EPS Beat/Miss
—
Price Before
$3.86
Price After
$3.86
Q1 FY2026+0.00%
Report Date
Mar 30, 2026
EPS Beat/Miss
-82.4%
Price Before
$3.86
Price After
$3.86
Q4 FY2025+5.66%
Report Date
Oct 27, 2025
EPS Beat/Miss
+2476.9%
Price Before
$5.30
Price After
$5.60
Q3 FY2025+0.00%
Report Date
Aug 20, 2025
EPS Beat/Miss
+92.1%
Price Before
$6.26
Price After
$6.26
Q2 FY2025+0.00%
Report Date
Apr 29, 2025
EPS Beat/Miss
-3335.0%
Price Before
$3.20
Price After
$3.20
Q4 FY2024+0.00%
Report Date
Dec 31, 2024
EPS Beat/Miss
-324.9%
Price Before
$4.00
Price After
$4.00
Q4 FY2024+0.00%
Report Date
Oct 29, 2024
EPS Beat/Miss
+103.5%
Price Before
$3.51
Price After
$3.51
Q3 FY2024+0.00%
Report Date
Aug 29, 2024
EPS Beat/Miss
+39.8%
Price Before
$1.98
Price After
$1.98
Avg Beat Reaction+1.42%
Avg Miss Reaction+0.00%
Beat Rate4 / 8 quarters
Largest Move+5.66% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CASBF ends December
CanSino Biologics Inc. (CASBF) most recently reported earnings on April 28, 2026 for Q2 FY2026, posting EPS of $-0.02 (in line with the analyst consensus of —). The next CASBF earnings date is expected around September 1, 2026.
Each quarter, investors track CASBF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CASBF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CASBF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CASBF earnings · 4 questionsCanSino Biologics Inc.'s next earnings report is expected around September 1, 2026. CASBF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CASBF historically reports after market close (AMC).
CASBF earnings datewhen is CASBF earningsCASBF next earnings datewhen does CASBF report earningsCASBF earnings calendar
▸ Source: FMP · CanSino Biologics Inc. SEC filings · US GAAP · CanSino Biologics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026